Kimberly M Walker

US Patent:

7201730, Apr 10, 2007

Filed:

Mar 17, 2003

Appl. No.:

10/391443

Inventors:

Alan A. Davidner - Yorba Linda CA, US
Kimberly A. Walker - Huntington Beach CA, US
Scott R. Mallett - Coto De Caza CA, US

Assignee:

Hemavation, LLC - Tustin CA

International Classification:

A61M 37/00
A61K 39/00
A61M 1/00
B01D 61/00

US Classification:

604 608, 604 501, 422 44, 4241401, 210646, 210651

Abstract:

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from , and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

US Patent:

7207964, Apr 24, 2007

Filed:

Mar 17, 2003

Appl. No.:

10/390558

Inventors:

Alan A. Davidner - Yorba Linda CA, US
Kimberly A. Walker - Huntington Beach CA, US
Scott R. Mallett - Coto De Caza CA, US

Assignee:

Hemavation, LLC - Irvine CA

International Classification:

A61M 37/00
C02F 1/44
B01D 11/00
B01D 61/00

US Classification:

604 608, 604 401, 604 501, 210645, 210650

Abstract:

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

US Patent:

7753869, Jul 13, 2010

Filed:

Apr 24, 2007

Appl. No.:

11/739574

Inventors:

Alan A. Davidner - Yorba Linda CA, US
Kimberly A. Walker - Huntington Beach CA, US
Scott R. Mallett - Coto De Caza CA, US

Assignee:

Hemavation, LLC - Tustin CA

International Classification:

A61M 37/00
C02F 1/44
B01D 11/00
B01D 61/00

US Classification:

604 608, 604 504, 604 601, 604 609, 604 613, 210645, 210650

Abstract:

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from , and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

US Patent:

20110006004, Jan 13, 2011

Filed:

Jul 12, 2010

Appl. No.:

12/834719

Inventors:

Alan A. Davidner - Yorba Linda CA, US
Kimberly A. Walker - Huntington Beach CA, US
Scott R. Mallett - Coto De Caza CA, US

Assignee:

HEMAVATION, LLC - Irvine CA

International Classification:

B01D 61/00
B01D 11/00
B01D 61/30
A61M 1/36

US Classification:

210639, 210646, 210259, 604 504

Abstract:

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from , and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.